Holen Sie sich die Stockscreener-App
5.59
1.82%
0.10
Handel nachbörslich:
5.59
Schlusskurs vom Vortag:
$5.49
Offen:
$5.57
24-Stunden-Volumen:
2.72M
Relative Volume:
1.00
Marktkapitalisierung:
$1.61B
Einnahmen:
$9.77M
Nettoeinkommen (Verlust:
$-109.00M
KGV:
-15.51
EPS:
-0.3604
Netto-Cashflow:
$-93.83M
1W Leistung:
+7.81%
1M Leistung:
-12.66%
6M Leistung:
+15.02%
1J Leistung:
+103.27%
1-Tages-Spanne:
$5.445
$5.695
1-Wochen-Bereich:
$5.17
$5.695
52-Wochen-Spanne:
$2.25
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.59 | 1.58B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance
Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 77% Upside in the Biotech Sector - DirectorsTalk Interviews
Taysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysis - MSN
Taysha (TSHA) Advances Clinical Development Strategy for TSHA-10 - GuruFocus
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Taysha Gene Therapies Q1 2026 earnings preview - MSN
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies Q1 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies Q1 2026 Earnings Call Transcript - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
TSHA: Pivotal trial dosing and regulatory milestones for TSHA-102 on track amid strong market demand - TradingView
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Nigeria
Taysha Gene Therapies: Runway to Fund Planned Operating Expenses Into 2028 >TSHA - Moomoo
TSHA: Pivotal trial dosing on track, strong efficacy and safety, and cash runway into 2028 - TradingView
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Taysha Gene Therapies | 10-Q: Q1 2026 Earnings Report - Moomoo
Taysha Gene Therapies Reports Q1 2026 Results, Advances TSHA-102 Pivotal Trials and FDA BLA Submission for Rett Syndrome Therapy - Minichart
Rising R&D spend widens Taysha Gene Therapies (NASDAQ: TSHA) Q1 loss - Stock Titan
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TSHA: Q1 2026 net loss widened to $42.4M as TSHA-102 pivotal trials advanced toward BLA submission - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway - Stock Titan
Taysha Gene Therapies Q1 net loss widens on higher R&D costs - TradingView
A 6-month trial readout could shape Taysha's gene therapy filing - Stock Titan
BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million - TradingView
Taysha Gene Therapies stock hits 52-week high at 6.77 USD - Investing.com Australia
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com - Investing.com South Africa
Taysha Gene earnings loom with pivotal trial data on horizon - Investing.com
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):